Product Information
ASPIRIN EC 325 MG TABLET is a generic product labeled by Rugby Laboratories, priced at $0.0222 per EA under NDC 00536123201. Its NADAC has been published 367 times since Sep 25, 2019.
Strength
325 mg/1
Manufacturer
Rugby LaboratoriesNDC
00536123201
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ASPIRINApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
6/1/2019
Pharmacological Classes
Price Statistics
The NADAC for ASPIRIN EC 325 MG TABLET has been published 367 times since Sep 25, 2019, and over the history we have for it it has risen 66.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0222 per EA |
|---|---|
| All-time high | $0.0240 (Apr 10, 2024) |
| All-time low | $0.0133 (Sep 25, 2019) |
| 52-week high | $0.0227 |
| 52-week low | $0.0212 |
| Median price | $0.0206 |
| Average price | $0.0197 |
| Largest weekly change | +19.9% (Aug 21, 2024) |
| Weeks tracked | 367 |
| Tracking since | Sep 25, 2019 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rugby Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aspirin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ASPIRIN EC 325 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ASPIRIN EC 325 MG TABLET, manufactured by Rugby Laboratories, is $0.0222 per EA (NDC 00536123201), effective Sep 30, 2026.
How has the price of ASPIRIN EC 325 MG TABLET changed over time?
Over the history we have for it, the NADAC for ASPIRIN EC 325 MG TABLET has risen 66.7%. It has been tracked across 367 weekly CMS publications since Sep 25, 2019.
What are the highest and lowest recorded NADAC prices for ASPIRIN EC 325 MG TABLET?
Since Sep 25, 2019, the NADAC for ASPIRIN EC 325 MG TABLET has ranged from a low of $0.0133 (Sep 25, 2019) to a high of $0.0240 (Apr 10, 2024), with a median of $0.0206 per EA.
Are there cheaper alternatives to ASPIRIN EC 325 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QC ASPIRIN 325 MG TABLET, is $0.0121 per EA — about 46% below ASPIRIN EC 325 MG TABLET.
Who manufactures ASPIRIN EC 325 MG TABLET?
ASPIRIN EC 325 MG TABLET (NDC 00536123201) is labeled by Rugby Laboratories, and CMS classifies it as a generic product.